

1.	Record Nr.	UNISALENTO991002450579707536
	Titolo	Il pensiero pedagogico / Giuseppe Flores D'Arcais ... [et al.]
	Pubbl/distr/stampa	Cavallino : Capone, [1988]
	Descrizione fisica	259 p. ; 21 cm
	Collana	Rileggere Pietro Siciliani ; 3 I nodi ; 6
	Altri autori (Persone)	Flores d'Arcais, Giuseppeauthor
	Disciplina	370.1
	Soggetti	Congressi - Lecce Siciliani, Pietro - Pensiero pedagogico
	Lingua di pubblicazione	Italiano
	Formato	Materiale a stampa
	Livello bibliografico	Monografia
2.	Record Nr.	UNINA9910495243103321
	Titolo	Identification of biomarkers, new treatments, and vaccines for COVID-19 // Paul C. Guest, editor
	Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2021] ©2021
	ISBN	3-030-71697-X
	Descrizione fisica	1 online resource (229 pages)
	Collana	Advances in experimental medicine and biology ; ; 1327
	Disciplina	614.592414
	Soggetti	COVID-19 (Disease) COVID-19 Marcadors bioquímics Terapèutica Vacunes Llibres electrònics
	Lingua di pubblicazione	Inglese
	Formato	Materiale a stampa
	Livello bibliografico	Monografia

Intro -- Preface -- Contents -- Part I: Background -- 1: Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement -- 1 Introduction -- 2 Epidemiology -- 3 Main Coronavirus Groups -- 4 Genome, Genotype, and Protein Structure -- 5 Mechanism of Infection -- 6 COVID-19 Pathogenesis -- 7 Respiratory Manifestations -- 8 Extra-pulmonary Presentations -- 8.1 Gastrointestinal Manifestations -- 8.2 Cardiovascular Complications -- 8.3 Haematological Disorders -- 9 Immune Responses -- 10 Therapy -- 10.1 Drugs that Slow Viral Replication or Kill SARS-Cov-2 -- 10.2 Vaccination -- 11 Conclusion -- References -- Part II: Epidemiology -- 2: Prevalence of COVID-19 and the Continued Citizen-Based Control in Japan -- 1 Introduction -- 2 Cruise Ship Outbreak and the Environmental Assessment -- 2.1 COVID-19 Outbreak on the Diamond Princess Cruise Ship -- 2.2 Age-Related CFR Estimated from the Cruise Ship Outbreak -- 2.3 Environmental Assessment of SARS-CoV-2 on the Cruise Ship -- 3 Government-Recommended and Voluntary Measures to Protect Against COVID-19 Infection in Japan -- 4 Detection of the Coronavirus in Laboratories in Japan -- 5 Conclusions -- References -- 3: COVID-19 Pandemic in Brazil: History, Characteristics, and Evolution -- 1 Brief Historical Facts of the COVID-19 Pandemic in Brazil -- 2 Governmental Measures to Combat the Pandemic -- 3 Regional Characteristics Influencing the COVID-19 Dissemination -- 4 Prevalence of the Disease in Different Subpopulations -- 5 Concluding Remarks -- References -- 4: The Experiences of Recovered COVID-19 Patients in Baqiyatallah Hospital: A Qualitative Study -- 1 Introduction -- 2 Methods -- 2.1 Data Collection -- 2.2 Data Analysis -- 3 Results -- 3.1 Theme I: Emotional-Sensational-Paradox -- Satisfaction-Dissatisfaction -- Positive Experiences-Negative Experiences. Relaxation-Stress -- Support-Rejection -- 3.2 Theme II: Spiritual Growth -- Accepting and Submitting to Divine Providence -- Rethinking Material Possessions -- Seeking Stronger Divine Connection -- Tendency to Spirituality -- 3.3 Theme III: Experienced Mental-Psychological Effects -- Unpleasant Thoughts -- Perceived Mental Stress -- Positive Thoughts -- 4 Discussion -- 5 Conclusions -- References -- Part III: Risk Factors and Outcomes -- 5: Age-Specific Differences in the Severity of COVID-19 Between Children and Adults: Reality and Reasons -- 1 Introduction -- 2 Age-Related Effects of Different Infections -- 3 Age Effects of COVID-19 Disease -- 4 Clinical Features in Children -- 5 The Different Etiology and Severity of COVID-19 Based on Age -- 6 Underlying Conditions and Severity of COVID-19 in Children -- 7 Outdoor Activities and the Potential to Contract the Virus -- 8 Immune System and Age-Related Differences -- 9 Innate Immune Cells and Age-Related Differences -- 10 IFN- and SARS-CoV in Children -- 11 Adaptive Immune Response and Age-Related Difference -- 12 Cross-Protection Against SARS-CoV-2 and Age-Related Differences -- 13 Improved Efferocytosis by Bacillus Calmette-Guerin (BCG) Vaccine to Protect Against COVID-19 Pneumonia -- 14 Age-Related Difference and Higher Hemoglobin in COVID-19 Pneumonia -- 15 The Role of Sex Hormones and Age-Related Differences in COVID-19 -- 16 Interferon as a Target Therapy in Coronavirus Disease 2019 (COVID-19) -- 17 The Role of Lactoferrin in Immune System Age-Related Differences -- 18 The Recommendations for Selecting Treatment in Patients Based on Age and Neutrophil-to-Lymphocyte Ratio (NLR) -- 19 Conclusions --

References -- 6: Sex Differences and COVID-19 -- 1 Introduction -- 1.1 COVID-19 -- 1.2 Sex and the COVID-19 Response. 2 Physiological Sex Differences as Potential Moderators of COVID-19 Outcomes -- 2.1 The Immune System and COVID-19 -- 2.2 Sex Differences in the Immune System -- 2.3 Sex Hormones and the Immune Response -- 2.4 Sex Hormones and COVID-19 -- 2.5 Sex Chromosomes and the Immune System -- 2.6 Ageing, Sex and the Immune System -- 3 Sex Differences in the Renin-Angiotensin-Aldosterone System -- 3.1 Sex Differences in the Renin-Angiotensin System and COVID-19 -- 4 Reproduction, Pregnancy and COVID-19 -- 5 Long-Term Outcomes of COVID-19 and Sex Differences -- 6 Conclusion and Perspectives -- References -- 7: Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known? -- 1 Introduction -- 1.1 Epidemiological Characteristics of Coronavirus Diseases -- 1.2 Coronavirus Disease 2019 (COVID-19) -- 2 Microbiota and Respiratory Infection -- 3 Potential Connections Between Intestinal Microbiota and COVID-19 -- 3.1 Age Effects -- 3.2 Hypertension -- 3.3 Diabetes -- 3.4 Obesity -- 4 COVID-19 and Microbiota -- 5 Conclusions and Future Perspectives -- References -- 8: SARS-CoV-2 Infection and the Kidneys: An Evolving Picture -- 1 Introduction -- 2 Dialysis -- 3 Transplant -- 4 Chronic Kidney Disease -- 5 Apo L1 -- 6 The Clinical Picture of Kidney Disease in COVID-19 -- 6.1 Acute Kidney Injury Pathophysiology -- 7 Conclusions -- References -- 9: Cutaneous Manifestations of COVID-19: Early Diagnosis and Prognostic Information -- 1 Introduction -- 2 Exanthem Pattern -- 2.1 Vesicular Eruptions or Varicella-Like Exanthem -- 2.2 Maculopapular Eruptions or Maculopapular Rash -- 3 Urticarial Lesions -- 4 Vascular Pattern -- 4.1 Acral Areas of Erythema with Vesicles or Pustules (Pseudo-Chilblain) -- 4.2 Purpuric/Petechial Lesions -- 4.3 Livedo or Necrosis -- 5 Acro-Papular Eruption -- 6 Treatment -- 7 Pathophysiological Mechanisms. 8 Conclusions -- References -- 10: How Do We Manage Breastfeeding During the COVID-19 Pandemic? -- 1 Introduction -- 2 Benefits of Breastfeeding -- 3 COVID-19 and Breastfeeding: Current Evidence -- 4 Guidelines on Breastfeeding for Mothers with Suspected or Confirmed COVID-19 -- 5 Conditions Recommended for Starting and Maintaining Breastfeeding -- 6 Conditions in Which It Is Recommended to Extract Breast Milk -- 7 Conditions in Which Recommended for Not Breastfeeding or Extracting Breast Milk -- 8 Breastfeeding by Mothers Undergoing Medications for COVID-19 -- 9 Conclusions and Future Perspectives -- References -- 11: Deep Learning Analysis in Prediction of COVID-19 Infection Status Using Chest CT Scan Features -- 1 Introduction -- 2 Methods -- 2.1 Study Design and Participants -- 2.2 CT Examination and Image Analysis -- 2.3 Statistical Analysis -- Comparisons Between Two Groups -- Deep Learning Analyzing and Classification -- 3 Results -- 3.1 Demographic Characteristics and Chest CT Findings -- 3.2 Deep Learning Analyzing Results -- 4 Discussion -- 5 Conclusions -- References -- Part IV: Treatments and Vaccines -- 12: Using Ozone Therapy as an Option for Treatment of COVID-19 Patients: A Scoping Review -- 1 Introduction -- 2 Methods -- 2.1 Inclusion Criteria -- 2.2 Search Strategy -- 3 Results -- 3.1 Extraction of Results -- 3.2 Protocols -- 3.3 Mechanism of Ozone as a Treatment -- 3.4 Ozone Therapy and Viral Infections -- 3.5 Ozone Therapy and Respiratory System -- Asthma -- Chronic Obstructive Pulmonary Disease (COPD) -- Pulmonary Emphysema -- 4 Discussion -- 5 Conclusions and Future Perspective -- References -- 13: COVID-19, Coenzyme Q10 and Selenium -- 1 Introduction -- 2 CoQ10 -- 3 Selenium -- 4

Oxidative Stress, Inflammation and Virus Infection -- 4.1 Oxidative Stress -- 4.2 Inflammation.

5 Supplementation CoQ10 and Selenium -- 6 Conclusions and Future Perspectives -- References -- 14: Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19) -- 1 Introduction -- 2 Agents with Known Effect Against SARS-CoV-2 -- 2.1 Alcohol and Isopropanol -- 2.2 Povidone-Iodine -- 2.3 Hydrogen Peroxide -- 2.4 Ultraviolet (UV) Radiation -- 2.5 Xylitol -- 2.6 Brilacidin -- 2.7 Carrageenan -- 3 Agents with Potential Effect on SARS-CoV-2 -- 3.1 Acid-Buffered Saline -- 3.2 Hypertonic Saline -- 3.3 Oxymetazoline and Xylometazoline -- 3.4 Probiotics -- 3.5 Chlorhexidine -- 3.6 Citrox (Flavonoids) and Cyclodextrins -- 3.7 Cetylpyridinium Chloride (CPC) -- 3.8 Surfactants/Shampoo -- 3.9 Interferon -- 4 Therapeutic Application and Method of Delivery -- 5 Conclusions -- References -- 15: Cinnamon: A Promising Natural Product Against COVID-19 -- 1 Introduction -- 2 Antiallergic Properties -- 3 Antiviral Properties -- 4 Cardiovascular Properties -- 5 Safety of Cinnamon -- 6 Conclusions and Future Perspectives -- References -- 16: Curcumin and Piperine in COVID-19: A Promising Duo to the Rescue? -- 1 Introduction -- 2 Curcumin-Piperine -- 3 Curcumin-Piperine and Virus-Induced Lung Injury -- 4 Curcumin-Piperine and Thrombosis -- 5 Safety of Curcumin-Piperine -- 6 Conclusions and Future Perspectives -- References -- 17: Association of In-hospital Use of Statins, Aspirin, and Renin-Angiotensin-Aldosterone Inhibitors with Mortality and ICU Admission Due to COVID-19 -- 1 Introduction -- 2 Methods -- 2.1 Study Design and Participants -- 2.2 Data Collection -- 2.3 Medication -- 2.4 Outcomes -- 2.5 Statistical Analysis -- 3 Results -- 4 Discussion -- 5 Conclusion -- References -- 18: The Worldwide Effort to Develop Vaccines for COVID-19 -- 1 Introduction -- 2 The SARS-CoV-2 Spike Protein.

3 SARS-CoV-2 Vaccine Candidates in Phase 3 Clinical Trials.
